This study focuses on detecting the possible beneficial effect of Lactoferrin (Lf) administration on the kidney and the heart of glycerol-induced rhabdomyolysis (RM) in rats and its relation to ferroptosis and AMPK/Nrf2/ HO-1 signalling pathway. The main questions it aims to answer are:
1. Is Lf administration 30 min. before or after RM induction in rats beneficial to kidneys and heart?
2. When administered to glycerol-induced rats, does Lf act by upregulating the AMPK/Nrf2/ HO-1 signalling pathway and inhibiting ferroptosis?

Start Date01 Nov 2024

Sponsor / Collaborator

Aswan University

NCT06654557 / RecruitingNot Applicable

Effect of Adding Glycerol to Electrolyte Beverages on Fluid Balance in Healthy Euhydrated Men and Women at Rest

The results of a prior study PEP-2311 suggested there was a positive dose-response effect of glycerol and sodium on fluid balance and fluid retention. In addition, inclusion of glycerol resulted in an upward shift in the relationship between sodium concentration and fluid balance. The practical interpretation is that addition of glycerol enables a reduction in sodium concentration compared with a 0% glycerol drink.
In this follow-up study, the investigators hypothesize that 1) fluid balance will be sustained (greater than or not different from baseline) and significantly greater than placebo for 120 min after drinking the test no/low/moderate carbohydrate beverages and 2) fluid balance will not differ between the carbohydrate-electrolyte beverages, but both will be greater than placebo.

Start Date07 Oct 2024

Sponsor / Collaborator

PepsiCo Global R&D

CTRI/2024/07/070899 / Not yet recruitingPhase 2/3IIT

A Clinical Study to Evaluate the effect of Ghritkumaryadi Aschyotan (Eye drops) with Glycerine in the Management of Computer Vision Syndrome - Nil

Start Date20 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Glycerin

100 Translational Medicine associated with Glycerin

100 Patents (Medical) associated with Glycerin

3,364

Literatures (Medical) associated with Glycerin

01 Feb 2025·VETERINARY RESEARCH COMMUNICATIONS

Impacts of adding sucrose or trehalose to extenders with different glycerol concentrations on freezablility and fertility of buffalo bull semen

Article

Author: Khalil, Wael A ; El-Deghaidy, Ragaey M ; Abdelnour, Sameh A ; Sakr, Abdelaziz M ; El-Harairy, Mostafa A ; Swelum, Ayman A

Abstract:

This experiment was conducted to determine the most suitable glycerol concentration (3 or 6%) and/or non-penetrating cryoprotectants (trehalose and sucrose) for the cryopreservation of buffalo semen, with the aim of enhancing the cryopreservation protocol. Semen of Egyptian buffalo were pooled and diluted with eight Tris extenders supplemented with either 6% glycerol (control group, GL6), 3% (low level, GL3), sucrose (SU, 50 mM), trehalose (TR, 50 mM), 6% glycerol together with 50 mM of sucrose (GL6SU) or 50 mM of trehalose (GL6TR), and 3% of glycerol together with 50 mM of sucrose (GL3SU) or 50 mM of trehalose (GL3TR), then frozen following the standard protocol. Findings indicated that GL3 extender resulted in the highest values of progressive motility, sperm kinematics, sperm membrane integrity, and viability of post-thawed semen (37 °C for 30 s). On the contrary, the Tris extender enriched only with SU and TR groups had the lowest values of sperm quality compared to the other groups (p < 0.05). All GL supplemented groups showed higher intact acrosome levels and lower detached acrosome and dead sperm with intact acrosome compared to those with TR and SU alone (p < 0.05). A significant increase in viable sperm was observed in the GL3, GL6, and GL3SU groups compared to the other groups (p < 0.05). The Tris extender supplemented with low glycerol (3%) significantly reduced the levels of MDA. In the in vivo fertility trial, it was shown that the pregnancy rate was higher in the GL6SU group (72%) than in the GL3SU group (68%; p > 0.05). Collectively, these results suggest that there is potential in using low glycerol (3%) as a cryoprotective agent in the medium for buffalo sperm cryopreservation without significant adverse effects compared to the addition of 6% glycerol. This study supported the sustainability of materials used in assisted reproductive technology by reducing the glycerol content in the freezing medium. Further research is needed to confirm this hypothesis.

01 Feb 2025·FOOD CHEMISTRY

Effects of different ratios of glycerol to erythritol on the structure and properties of starch straws during long term storage

Article

Author: Du, Xianfeng ; Guo, Li ; Xia, Chuanjin ; Wang, Guoqing ; Ma, Chenyu ; Cui, Bo ; Wang, Jinpeng ; Sun, Chunrui

To explore starch straws with low water absorption rate (WAR) and not prone to brittleness during long term storage. Glycerol and erythritol were used as composite plasticizers to explore their effects on the structure of starch straws. The results showed that G:E (60:40) had the lowest bending force (Fb = 12.58 N) and relative crystallinity (RC = 10.05 %). G:E (40:60) had the lowest water absorption rate. With the increase of erythritol contents, the proportion of starch straws short chains (A + B1) increased. Starch straws are easier to be broken during long term storage as the percentages of erythritol increased from 80 to100. However, G:E (40:60) and G:E (60:40) not only had higher flexibility (Eb = 6.12 N/cm and 7.47 N/cm) but greater hardness (Fb = 39.37 N and 45.42 N). Therefore, the addition of glycerol can inhibit the precipitation of erythritol and has an ideal plasticizing effect than single plasticizer.

01 Jan 2025·REGULATORY TOXICOLOGY AND PHARMACOLOGY

Minimizing the risk of ethylene glycol and diethylene glycol poisoning in medications: A regulatory and pharmacopoeial response

Article

Author: Saini, Pawan Kumar ; Sahoo, Saurabh ; Kumar, Pawan ; Rastogi, Shruti ; Jadaun, Gaurav Pratap Singh ; Raghuvanshi, Rajeev Singh

Pharmaceutical and personal care products, including syrups and toothpastes, extensively use glycerin, sorbitol, and propylene glycol. However, past incidents of ethylene glycol (EG) and diethylene glycol (DEG) contamination in these products have raised serious health concerns. Recently, several child deaths linked to contaminated cough syrup consumption have heightened concerns regarding the safety of Indian pharmaceuticals. In response, Indian drug regulatory authorities and the Indian Pharmacopoeia have implemented several measures to enhance the quality, safety, and efficacy of pharmaceuticals manufactured in India. These measures encompass risk-based inspections of manufacturing facilities, rigorous quality control checks of medicinal products intended for export, and increased transparency in the supply chain of excipients prone to EG and DEG contamination. Further, the Indian Pharmacopoeia has updated monographs for five high-risk excipients: glycerin, propylene glycol, sorbitol solution (70%, both crystallizing and non-crystallizing), and liquid maltitol. These efforts are consistent with global regulatory standards and aim to ensure the overall quality and safety of pharmaceuticals produced in India.

News (Medical) associated with Glycerin

10 Jun 2024

·www.biospace.com

Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company’s proprietary OpticAlign® design, INFUSE for Astigmatism provides astigmatic patients clear, stable vision, all-day comfort and minimizes contact lens dryness. The company expects to start shipping INFUSE for Astigmatism fitting sets to eye care professionals in July 2024. “More than half of toric lens wearers with astigmatism experience contact lens dryness and many also report blurred vision. These symptoms are only exacerbated with modern-day lifestyles, which include prolonged digital device use,”1 said Yang Yang, president, Global Vision Care, Bausch + Lomb. “Our INFUSE for Astigmatism lenses, which were developed in-house by our R&D team, are designed to directly address these challenges, including the causes of toric lens rotation. They provide excellent clarity, optimal stability and can be worn comfortably all day.” Consistent with the entire INFUSE family of lenses, INFUSE for Astigmatism features a blend of osmoprotectants, electrolytes and moisturizers, essential comfort and eye health ingredients that are released throughout the 16-hour wearing experience.1 The lens material (kalifilcon A) combines the highest overall moisture (55%) and high breathability (107 Dk/t) with a low modulus for excellent comfort.2,3 INFUSE for Astigmatism is uniquely designed to provide consistently clear vision across the entire power range and help reduce spherical aberration and halos and glare, even in low-light conditions. Engineered with a thin-edge design to minimize lid interaction and a stabilization feature in the lower hemisphere, the cutting-edge OpticAlign design stabilizes with the eye’s natural blink. According to a recent study, 95% of INFUSE for Astigmatism lenses settled within 10 degrees within 30 seconds. In addition, 97% of INFUSE for Astigmatism lenses had less than three degrees of rotation with blink and a mean comfort score of nearly 90%. INFUSE for Astigmatism offers the most in-office parameters and is the only daily disposable toric with -2.25 and -2.75 cylinders available in a fit set.4 "As patient lifestyles become increasingly more dynamic, it's essential their lenses provide a high level of moisture retention and stability, particularly for those with astigmatism. INFUSE for Astigmatism will deliver on these needs and provide comprehensive in-office parameters that make it possible to fit patients during their scheduled appointment,” said Mark Schaeffer, OD, FAAO, and clinical excellence captain, MyEyeDr, Birmingham, Ala. “With this addition to the INFUSE family of lenses – based on the latest ocular surface research – practitioners can be confident that they have an INFUSE lens to meet the majority of their patients’ vision and eye health needs.” Eye care practitioners and contact lens wearers can use Bausch + Lomb’s ONE by ONE recycling program to properly recycle their used contact lens materials, including INFUSE for Astigmatism contact lenses, blister packs and top foils. For more information on the ONE by ONE Recycling program visit . About Astigmatism Astigmatism is a common condition that affects approximately one in three people and occurs when the cornea or lens has a different shape than normal, causing blurry or distorted vision.5,6 It can affect vision of both near and far objects, as well as cause difficulty seeing at night, and coexist with myopia or hyperopia. Astigmatism can be confirmed during a comprehensive eye exam and treated with the use of contact lenses, prescription eyeglasses and/or laser or other surgical procedures.6 About the ONE by ONE Recycling Program The Bausch + Lomb ONE by ONE Recycling program is the first and only contact lens recycling program in the United States. This program collects used contact lenses, top foils and opened plastic blister packs from any brand and is available to contact lens wearers and eye care professionals. To participate, contact lens wearers can bring their used contact lenses and packaging to an official recycling eye care practice, which collects the used materials in a custom recycling bin provided by Bausch + Lomb. Once the bin is filled, the eye care practice ships the materials using a Bausch + Lomb pre-paid shipping label to TerraCycle® where lenses are cleaned and melted into hard plastic pellets that can be used to make new recycled products. To learn more about the Bausch + Lomb ONE by ONE Recycling program, visit . About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on X, LinkedIn, Facebook and Instagram. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. References Analysis of worn lenses demonstrated poloxamer 181, erythritol, potassium, and glycerin were retained for 16 hours. Oxygen transmissibility at -3.00 diameter. Unlike INFUSE® for Astigmatism, ACUVUE OASYS 1-Day for ASTIGMATISM, MyDay toric, and 1-DAY ACUVUE MOIST for ASTIGMATISM, which are non-surface-treated daily disposables, PRECISION1 for Astigmatism and DAILIES TOTAL1 for Astigmatism are daily disposables with an integrated surface coating. Compared to ACUVUE OASYS 1-Day for ASTIGMATISM, DAILIES TOTAL1 for Astigmatism, and MyDay toric. National Eye Institute: Astigmatism: At a Glance. Accessed May 13, 2024. . Cleveland Clinic: Astigmatism. Accessed May 13, 2024. . © 2024 Bausch + Lomb. IFA.0080.USA.24 View source version on businesswire.com: Contacts Source: Bausch + Lomb Corporation View this news release online at:

29 Apr 2024

·www.biospace.com

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

21 Poster Presentations include Evaluations of Consumer, Pharmaceutical, Surgical and Vision Care Products and Pipeline Programs, Including a Novel Dry Eye Nutritional Supplement VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Seattle May 5-9, 2024. The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations. These include a novel daily nutritional supplement formulated to address dry eye symptoms, which is the focus of two posters as well as a paper published recently in Frontiers in Ophthalmology. “We’re focused on supporting research that advances scientific knowledge of our products and fosters the development of new innovations to serve the holistic needs of eye care professionals and consumers,” said Yehia Hashad, MD, executive vice president, Research & Development and chief medical officer, Bausch + Lomb. “The breadth of data being presented at this meeting, as well as the recent publication evaluating our novel nutritional supplement for dry eyes, Blink™ NutriTears®, underscore this ongoing commitment.” Following is a complete list of titles and lead authors for each of these posters: “Analysis of Glare and its Impact on Retinal Image Quality in Intraocular lenses.” Hosten et al. “A Natural Language Processing Approach to Identify Patients with Uveitic Macular Edema in the IRIS® Registry.” Jin et al. “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Barbour et al. “Clinical Evaluation of a Novel Lipid-Containing Eye Drop.” Yassine et al. “Comparison of Clinical Studies from the US and India of a Multi-Ingredient Oral Supplement.” Ryan et al. “Comparison of a Novel Lipid Nano-Emulsion Eye Drop with an Existing Lubricating Eye Drop.” Morrow et al. “Development of an In Vitro Assay to Evaluate the Antioxidant Effects of Erythritol and Glycerin in Human Corneal Epithelial Cells.” VanDerMeid et al. “Effects of Perfluorohexyloctane on the Ocular Pharmacokinetics of Latanoprost and Prednisolone Acetate After Topical Administration to Rabbits.” Cavet et al. “Effects of Perfluorohexyloctane on Corneal Healing in an Ex Vivo Study of Rabbit Corneas.” Alexander et al. “Efficacy of Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Stratified by Baseline Severity.” Sheppard et al. “Enhancing Silicone Oil Removal Efficiency: A Comparative Study of Ultrasonic Vitrectomy Handpieces and Conventional Methods.” Higgins et al. “Evaluating a Novel Contact Solution Among Hydrogen Peroxide Lens Care Users.” Shahidi et al. “Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” DiVito et al. “Evaluation of Intermediate-Range of Focus with New Monofocal Plus IOLs.” Lau et al. “Evaluation of the Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Vollmer et al. “Impact of Pupil Size on Vision Performance of a New Multifocal Daily Disposable Contact Lens.” Reindel et al. “In-Home Use Test of a Novel Contact Lens Solution in Contact Lens Wearers on the Verge of Dropout.” Rah et al. “Intraocular Pressure Optimized Performance Settings with Posterior Adaptive Fluidics (PAF), and 25 Gauge 25,000 cpm Dual-Action Vitrectomy Cutters.” Papour et al. “Phaco Longitudinal Mode Heat Generation, a Two-System Efficiency Comparison Study.” Dickerhoff et al. “Preclinical Toxicity Pro Perfluorohexyloctane Ophthalmic Solution.” Vittitow et al. “Predictive Modeling of Clinical Performance of Novel Trifocal IOL.” Venkateswaran et al. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on X, LinkedIn, Facebook and Instagram. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. © 2024 Bausch + Lomb.

06 Feb 2024

·www.prnewswire.com

SUNLESS INC. STEPS INTO BEAUTY, MERGING SCIENCE AND TECHNOLOGY TO CREATE WELLFIT™, AN EFFORTLESS FULL-BODY SKINCARE EXPERIENCE

CLEVELAND, Feb. 6, 2024 /PRNewswire/ -- Sunless, Inc., the company behind VersaSpa® skincare spray systems, today announced the launch of WELLFIT™, a smarter solution to empower healthy full-body confidence in two minutes or less. WELLFIT offers three unique skincare solutions — HYDRATE, LIFT, and RECOVER — as a stand-alone treatment or as an add on to other wellness services to restore, revive and recover the skin's health, boasting a difference users can feel and see. Continue Reading New skincare solution helps restore, revive and recover the skin's health, boasting a difference users can feel and see. Post this Sunless, Inc.'s WELLFIT is a smarter solution to empower healthy full-body confidence in two minutes or less. View PDF Sunless, Inc., makers of VersaSpa® products, steps into beauty, merging science and technology to create an effortless full-body skincare experience. WELLFIT's unique, first-of-their-kind skincare treatments are delivered in a customized spray system offered at participating VersaSpa Pro fitness clubs and tanning salons. WELLFIT has been previewed at several locations throughout the country. More than 85% of users say they "love the way the treatments make the skin feel." WELLFIT users who have experienced the treatments have raved about the difference in their skin, sharing that their usually dry skin felt baby soft and tighter overall after enjoying their refreshing treatment. WELLFIT addresses the need for more approachable skin-focused wellness options, with a recent McKinsey & Co. Future of Wellness survey* citing that 50% of U.S. consumers report wellness as a top priority in their lives, with "better skin appearance" sited as an important pillar in their wellness routine. "The launch of WELLFIT skincare solutions brings to life more than 40 years of skin expertise, combined with smart innovation and technology to produce healthy, glowing skin for all," said Randy Zeno, Sunless, Inc. CEO. This revolutionary concept combines smart technology with unparallel skincare options crafted with clinically tested formulas by Sunless's team of skincare experts. The solutions feature skin-loving ingredients such as hyaluronic acid, vitamins, and essential peptides providing moisture, strength, and a long-lasting glow for healthy-looking skin. This effortless approach to healthy, radiant skin redefines self-care by simplifying your routine and allowing you to focus on feeling your most confident self. WELLFIT is proven to rejuvenate the senses with the infused scents of sea grass and sage. THE WELLFIT EXPERIENCE HYDRATE – Quenches the thirst skin craves. Patented Tri-Hydro Boost Complex™ features a unique formula that allows skin to soak up all the moisture it desires. Active humectants such as glycerin draw moisture deep into the skin, providing immediate suppleness. Impacts multiple layers of skin, restoring the moisture barrier of the skin. The refreshing blend improves skin health maximizing long-term skincare performance. LIFT – Delivers all the firm plumpness skin desires. Features a powerful C-Lift Peptide Complex™ known for its collagen-boosting properties, including vitamins and essential peptides. Helps replenish and restore collagen levels, making skin look healthier, plumper, brighter, and younger. Skin feels instantly smoother, visibly reducing the appearance of surface wrinkles and imperfections for the ultimate firming pick me up. RECOVER – Invigorates your skins health. Crucial electrolytes refuel fatigued skin post activity, providing total body recovery and vital elasticity for skin that bounces back. The activated Nitro+Mineral Complex™ features a cooling blend that instantly energizes the skin's sensations to make it come alive. Vital minerals infuse with the skin to restructure vibrancy and texture for recovery. WELLFIT is available at Sunless, Inc. partner locations in the U.S. and is launching at other locations across the globe throughout the year. WELLFIT will be adding more treatments and skincare products throughout 2024. WELLFIT skincare solutions are here to empower on-the-go, active-lifestyle enthusiasts. All solutions were created to be used as daily treatments, up to three times a week for optimal results. About Sunless/VersaSpa Sunless Inc. is a leader in spray tanning and skincare technology and the power behind the best-known brands — Mystic Tan, Norvell, and VersaSpa — representing more than 18 million spray tans per year, delivered by more than 7,000 salons and professionals worldwide. A holding of Castle Harlan and Branford Castle, Sunless, Inc. is headquartered in Macedonia, Ohio. For more information, images, or quotes from Sunless, Inc., contact Jim Cyphert, APR at 330-501-9886. For more information and available locations, visit: . Instagram: @wellfit.skincare Facebook: wellfit skincare *McKinsey Future of Wellness survey, April 2022, n=2000 SOURCE Sunless, Inc.

100 Deals associated with Glycerin

External Link

KEGG	Wiki	ATC	Drug Bank
D00028	Glycerin	A06AX01 A06AG04	DB09462

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Constipation	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02833415 (CTgov)	Phase 4	Obesity, Abdominal \| Diabetes Mellitus	40	[U-13C3] glycerol+Empagliflozin (Empagliflozin)	bosasgvjji(sjblbtqwnc) = lazsxudxgx zdkemjjzln (tlhkjzzehf, rrknpvggzt - zhiuxvkvur) View more	-	02 May 2019
				Placebo (for Empagliflozin)+[U-13C3] glycerol (Placebo)	bosasgvjji(sjblbtqwnc) = calpyefpaw zdkemjjzln (tlhkjzzehf, uzqchcjbdz - cqiyniaxoz) View more
NCT02383758 (CTgov)	Not Applicable	Autism Spectrum Disorder \| Autistic Disorder \| Stool soiling	22	Glycerin Suppository+Bisacodyl suppository+Senna (Treatment Program)	yorxihnaxf(wtlrchbtrp) = yqgtcgtenp oamiolrngi (ffelnmknqs, bydptyohpk - slqubfkyvz) View more	-	11 Jan 2018
				Glycerin Suppository+Bisacodyl suppository+Senna (Waitlist Control)	yorxihnaxf(wtlrchbtrp) = kozecelbxs oamiolrngi (ffelnmknqs, lmlrhgaolv - iasffrzhjc) View more
AUA2017	Not Applicable	Visceral Pain	-	JZL 184	(wcfxtsrcrg) = pvqvmauvfh jizpfvyeku (mjzzzupwvk )	-	01 Apr 2017
				Vehicle	(wcfxtsrcrg) = xlcfybxuas jizpfvyeku (mjzzzupwvk )
TROG 04.01 (Pubmed \| Int J Radiat Oncol Biol Phys)	Not Applicable	-	333	Moisturizing Durable Barrier Cream	adxkotmatm(sxydutthkm) = dggoqycclj zloxymbawz (gxevybryuc )	-	01 May 2013
				10% Glycerine Cream	adxkotmatm(sxydutthkm) = qcydbokxzf zloxymbawz (gxevybryuc )
NCT00681265 (CTgov)	Not Applicable	Kerato conjunctivitis sicca	16	Glycerin (New Formulation of Glycerin 1% Eye Drop)	xipfywfeha(qqgeoevkzh) = yolyuwnaqg yoklpciijx (jmyxvosdos, esdlabkqzx - ridmloxsxx) View more	-	26 Oct 2012
				Propylene Glycol+PEG 400 (Propylene Glycol and PEG 400 Eye Drop)	xipfywfeha(qqgeoevkzh) = tcczjxhips yoklpciijx (jmyxvosdos, ovpfcwvvdg - cijnafbesu) View more
SFN2011	Not Applicable	-	-	2-arachidonoyl-glycerol (2-AG)	cohajgjxph(iizlmbpoyo) = fsjwischmc gdsgxnpsys (sozffhfkdz ) View more	-	16 Nov 2011
NCT00333671 (Pubmed \| Invest Ophthalmol Vis Sci)	Not Applicable	Bloodshot eye \| Diabetic macular oedema	18	Peroral Glycerol	ydcksobuiv(aavxlvkkht) = unozwtkovr pwpmdkrnwp (sqmhpsmhbi )	-	01 Jun 2010
				Peroral Glycerol	ydcksobuiv(aavxlvkkht) = agwlxuygvh pwpmdkrnwp (sqmhpsmhbi )
NCT00681265 (ARVO2009)	Not Applicable	Kerato conjunctivitis sicca	16	New formulation of glycerin 1%	yolkjcdjli(oldecdwhmx) = avrrllwtbk fwqzrkowyt (phziyqcwfm ) View more	-	01 Apr 2009
				Commercially available artificial tear formulation of propylene glycol (0.3%) and polyethylene glycol (0.4%)	wgjbbdkrqh(sxbegsdthj) = xfeznxcqdm hylpvyuztx (odxpjjegmo )
SFN2003	Not Applicable	-	-	H2O2	htqlhukwyv(muargpshdc) = vxugtdheds khqfbeahop (dchkwjvnje )	-	12 Nov 2003
ARVO2003	Not Applicable	-	-	Glycerin	arwqoolqlt(pimgnmrqwc) = jnigxxllsn ijbqtsbdni (whemkqhjxc )	-	01 May 2003
				Glycerin (Dimethyl Sulfoxide (DMSO))	arwqoolqlt(pimgnmrqwc) = tlyzubjxfl ijbqtsbdni (whemkqhjxc )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis